U.S. market Closed. Opens in 11 hours 45 minutes

TALS | Talaris Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2022-12-312021-12-312020-12-312019-12-31
RevenueN/AN/AN/AN/A
Cost of RevenueN/AN/AN/AN/A
Gross ProfitN/AN/AN/AN/A
Operating Expenses76.48M47.51M22.68M18.38M
Selling, General & Admin19.47M13.26M7.41M5.01M
Research & Development57.01M34.24M15.28M13.37M
Other Operating ExpensesN/AN/AN/AN/A
Operating Income-76.48M-47.51M-22.68M-18.38M
Other Expenses / Income2.58M-326.00K-23.00K223.00K
Before Tax Income-73.89M-47.83M-22.71M-18.16M
Income Tax Expenses-5.17M326.00K23.00K-223.00K
Net Income-68.73M-48.16M-22.73M-17.93M
Interest Expenses2.58M-326.00KN/AN/A
Basic Shares Outstanding4.12M2.91M668.51K638.33K
Diluted Shares Outstanding4.12M2.91M668.51K638.33K
EBITDA-74.31M-46.88M-22.24M-18.00M
EBITDA Margin0.00%0.00%0.00%0.00%
EBIT-71.31M-48.16M-22.71M-18.16M
EBIT Margin0.00%0.00%0.00%0.00%
Financial Year End2022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙